Drug Trial Radar · NCT00872729
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
May 2009
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 31, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cystinosis is an inheritable disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results.
Conditions
- Cystinosis
Interventions
Cystagon®Drug
Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg. Duration of Treatment and Dose: Reference Period up to four doses Q6H.
RP103Drug
Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg. Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Pharmacokinetic Parameter: Cmax of CysteamineTime frame: 12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing
- Plasma Pharmacokinetic Parameter: Tmax of CysteamineTime frame: 12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing
- Plasma Pharmacokinetic Parameter: AUC(0-t) of CysteamineTime frame: 12 hours post RP103 dosing and 6 hours post 1st Cystagon® dosing
- Pharmacodynamic Parameter: Changes of White Blood Cell (WBC) Cystine Level From BaselineTime frame: up to 12 hours post Cystagon® dosing and RP103 dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Diego Medical Center
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.